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Abstract
Cyclooxygenase-2 (COX-2) has been implicated in the
development of gastrointestinal malignancies. The aim
of the present study was to determine COX-2 expres-
sion/activity throughout stages of experimental and
human pancreatic neoplasia. COX-2 immunohisto-
chemistry was performed in pancreata of hamsters
subjected to the carcinogen N-nitrosobis-(2-oxo-
propyl)amine (BOP) and in human pancreatic tumors.
COX-2 activity was determined by prostaglandin E2
assay in tumor versus matched normal pancreatic
tissues. The activity of the COX inhibitor sulindac was
tested in the PC-1 hamster pancreatic cancer model.
COX-2 expression was elevated in all pancreatic intra-
epithelial neoplasias (PanINs) and adenocarcinomas.
In BOP-treated hamsters, there were significant pro-
gressive elevations in COX-2 expression throughout
pancreatic tumorigenesis. In human samples, peak
COX-2 expression occurred in PanIN2 lesions and
remained moderately elevated in PanIN3 and adeno-
carcinoma tissues. COX-2 activity was significantly
elevated in hamster and human pancreatic cancers
compared to pair-matched normal pancreas. Further-
more, hamster pancreatic tumor engraftment/formation
in the PC-1 hamster pancreatic cancer model was
reduced 4.9-fold by oral administration of sulindac.
Increased COX-2 expression is an early event in pan-
creatic carcinogeneses. The BOP-induced hamster
carcinogenesis model is a representative model used
to study the role of COX-2 in well-differentiated pan-
creatic tumorigenesis. COX inhibitors may have a role
in preventing tumor engraftment/formation.
Neoplasia (2006) 8, 437–445
Keywords: Pancreatic neoplasms, PanIN, COX-2, chemical carcinogenesis,
sulindac.
Introduction
Pancreatic cancer is the fourth most common malignancy in
the United States. The annual incidence of pancreatic
cancer is approximately 33,730 cases [1]. Treatment options
for pancreatic cancer are very limited [2]. A minority of patients
are surgical candidates, and even those patients who undergo
surgical treatment have, at most, a 5-year survival rate of 15%.
All other treatments for pancreatic cancer are, for the most
part, palliative and provide little hope of cure.
A better understanding of the molecular changes that occur
in the process of pancreatic carcinogenesis may lead to better
treatment and/or chemopreventive strategies. Cyclooxyge-
nase-2 (COX-2) has been implicated in the development of
colon and other human epithelial malignancies [3–6]. COX-2
catalyzes the conversion of arachidonic acid to prostaglandin
E2 (PGE2) and a variety of other prostanoids, some of which
appear to stimulate cancer cell proliferation, inhibit apoptosis,
and/or induce angiogenesis [5,7–13]. COX-2 inhibitors have
been demonstrated to cause the regression of adenomatous
polyps—the precursor lesions of colon cancer [4,6].
The role of COX-2 in pancreatic carcinogenesis is less clear.
Several investigators have demonstrated elevated COX-2
protein or mRNA in pancreatic adenocarcinomas compared
to pair-matched normal tissues [10,14–25]. The principal aim
of our study was to further characterize the role of COX-2 in
pancreatic carcinogenesis by measuring COX-2 protein expres-
sion in each of the successive stages of both experimental and
human pancreatic carcinogeneses. These stages are charac-
terized by pancreatic intraepithelial neoplasia (PanIN) [26] (i.e.,
PanIN1, PanIN2, and PanIN3) and, ultimately, invasive adeno-
carcinoma. For these experiments, we used a N-nitrosobis-(2-
oxopropyl)amine (BOP) chemically induced hamster pancreatic
cancer model system because it is widely used in pancreatic
cancer studies, and we compared the results to those obtained
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from studies on the human pancreas. Secondly, we tested
the hypothesis that COX-2 enzymatic activity is elevated in
pancreatic cancer by assaying PGE2 levels in hamster and
human tumors versus pair-matched normal tissues. Finally,
we tested the antitumor activity of the nonselective COX in-
hibitor sulindac in the PC-1 hamster pancreatic cancer model.
Our findings lend further support for the hamster BOP model
system as a relevant model for human pancreatic neoplasia
and suggest that COX-2 may be relevant both early in neo-
plasia and later in tumor formation and engraftment.
Materials and Methods
Assurances
These studies have been conducted in strict compliance
with the Indiana University School of Medicine Institutional
Review Board and with the Indiana University–Purdue Uni-
versity Indianapolis Science Institutional Animal Care and
Use Committee.
Animals
Experimental pancreatic carcinogenesis was initiated by
exposing male Syrian golden hamsters to the carcinogen
BOP. Beginning at time 0, 30 hamsters were given three
weekly (20 mg/kg) intraperitoneal injections of BOP. On
week 42, the animals were euthanized, and the pancreas
was preserved in 10% neutral-buffered formalin. The tissues
were processed and embedded in paraffin, 5-mm sections
from four different areas of each pancreas were stained with
hematoxylin and eosin (H&E), and neoplastic lesions were
scored by a pathologist, as described previously [27]. An ad-
jacent section from each sample was processed for COX-2
immunohistochemistry (see below). A related model (PC-1
hamster pancreatic cancer model) was employed to measure
in vivo PGE2 levels and to assess the effects of the non-
selective COX inhibitor sulindac. Male Syrian golden ham-
sters weighing 90 to 100 g were injected subcutaneously
with the PC-1 cell line (1  106 cells) [28], which was origi-
nally established from a BOP-induced Syrian golden hamster
pancreatic ductal adenocarcinoma in the model described
above. Tumor-bearing animals were euthanized, and PGE2
levels were measured in PC-1–derived tumors and in nor-
mal pancreas from the same animal. In the sulindac study,
hamsters were given a purified, nutritionally complete Teklad
hamster diet 96224 (Harlan-Teklad, Indianapolis, IN) [27] or
sulindac (Sigma, St. Louis, MO) as 0.01% (wt/wt) of the same
diet for 5 days before the flank injection of PC-1 tumor cells.
Animals continued on their respective diets throughout the
experiment. The presence or absence of a tumor > 2 mm in
diameter was determined twice weekly for 4 weeks, and
tumor incidence percentage was calculated as: (number of
tumor-bearing animals/total number of animals)  100.
Immunohistochemistry
Immunohistochemistry was performed after deparaffinizing
the slides in xylene followed by three ethanol and one
phosphate-buffered saline (PBS) washes. Slides were then
microwave-heated in 5 mM sodium citrate (Fisher, Pitts-
burgh, PA) buffer, allowed to cool, and washed with PBS,
3% hydrogen peroxide (Sigma), and PBS again. Slides were
then blocked for 15 minutes with nonfat dry milk (0.3 g/10 ml
water), incubated with the primary COX-2 antibody (Cayman
Chemical, Ann Arbor, MI) for 90 minutes at 37jC, and then
washed in PBS. Slides were then exposed to secondary
antirabbit antibody (Biogenex, San Ramon, CA) for 30 min-
utes at room temperature and then washed with PBS. This
was followed by exposure to streptavidin peroxidase (Bio-
genex) for 30 minutes at room temperature, followed by
washes in PBS and water. a-Ethyl carbazol (Zymed, South
San Francisco, CA) and diaminobenzidine tetrahydrochloride
(Sigma) were used as chromagens for the hamster and hu-
man slides, respectively. Hematoxylin (Fisher) was used as
counterstain. COX-2 expression was determined in human
and hamster pancreas independently by board-certified
pathologists. Hamster lesions were graded according to the
most advanced lesion present in the pancreata on a point
intensity scale from 0 to 2 (0 = absent/weak; 1 = intermediate;
2 = intense staining). A separate pathologist independently
graded the human lesions by intensity and frequency of
staining. The intensity of staining was scored on a scale of
0 to 3 (0 = absent; 1 = faint; 2 = intermediate; 3 = strong), and
the percentage of cells stained was scored on a scale of on
a point scale from 0 to 4 (0 = 0%; 1 = 1–5%; 2 = 6–25%; 3 =
26–50%; 4 = greater than 50%). Differences in COX-2 ex-
pression were determined in normal ductules, normal ducts,
PanIN1–PanIN3 lesions, and invasive cancers. A normal
ductule was defined as a duct surrounded by normal-
appearing acinar architecture that had no more than one-
epithelial-cell-layer-thick connective tissue stroma. A normal
duct in our study was defined as a duct with greater than
one-cell-thick stroma surrounding it, which is not necessarily
surrounded by normal acinar architecture. COX-2 expression
was also assessed in cancers according to differentiation
status. Contiguous lesions or lesions that appeared architec-
turally (on serial slices) to connect to other lesions within
the ductal system were not double-counted and were con-
sidered part of the same lesion. In invasive cancers and oc-
casionally in PanIN lesions, there was heterogeneity of
COX-2 staining. In such cases, the tumor was divided ran-
domly into 20 field regions analyzed. The number of 20
fields depended on the size of the tumor represented on
the slide. Within each 20 field, the intensity and frequency
of COX-2 staining were determined. The average of the
20 fields served as the COX-2 score for each lesion that
had significant heterogeneity.
Statistical analysis in human specimens was performed
by generating a COX-2 expression score for each ductule,
duct, PanIN1–PanIN3, and invasive cancer, which was the
multiplicative factor of the intensity times the frequency of
cells stained. All of the human data were then analyzed
according to neoplastic stage with an overall ‘‘average
score,’’ where equal weighting was given for each identified
lesion of the same stage within the same specimen. For
example, if a single human specimen had three separate
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PanIN2 lesions identified, each PanIN2 lesion would count
in the average of all PanIN2 lesions across all of the speci-
mens. Because of the possibility of bias with this method,
all of the human data were also analyzed according to neo-
plastic stagewith a ‘‘composite score,’’ where each specimen
could only count once toward any particular stage of neo-
plasia. For example, if a single human specimen had three
separate PanIN2 lesions identified, their scores would be
averaged to generate only one ‘‘composite’’ score in the
average of all PanIN2 lesions across all of the specimens.
PGE2 Assay
Cryopreserved tumor specimens and pair-matched nor-
mal tissues were homogenized in ice-cold 50 mM Tris–HCl,
pH 7.4 (5 ml/g tissue), containing 10 mg/ml of the COX in-
hibitor indomethacin and pelleted by centrifugation (150g 
10minutes). The resultant pellet wasdiscarded, andhomoge-
nates were adjusted to a final protein concentration of ap-
proximately 6 mg/ml. PGE2 was extracted from 0.5 ml of the
resulting homogenate by adding 0.5 ml of a water/ethanol
(1:4) solution and 10 ml of glacial acetic acid, mixing gently,
and incubating at room temperature for 5 minutes. After spin-
ning, supernatants were loaded onto a primed Amprep C18
minicolumn (Amersham, Piscataway, NJ). The column was
washed with distilled water followed by hexane. PGE2 was
eluted with ethyl acetate, and resulting fractions were evap-
orated to dryness under nitrogen. Samples were reconsti-
tuted in 200 ml of assay buffer (supplied in PGE2 kit), and
10 ml was assayed for PGE2. Each sample was assayed in
duplicate following the recommended protocol. The assay is
based on the competition between unlabeled PGE2 and a
fixed quantity of peroxidase-labeled PGE2 for binding to a
PGE2-specific antibody bound to a plate coated with goat
antimouse immunoglobulin. The amount of bound PGE2
peroxidase can be measured by the addition of the sub-
strate. After the addition of sulfuric acid to stop the reaction,
the plate is read at 450 nm. PGE2 levels were compared with
COX-2 expression in the same samples to determine the
functional activity correlated with COX-2 protein expression.
Western Blot Analysis
Cryopreserved tumor specimens and pair-matched normal
tissues were homogenized in ice-cold 50 mM Tris–HCl (pH
7.4) containing 1 mM EDTA, 1 mM sodium vanadate, and
1 tablet of Complete Protease Inhibitor (contains leupeptin,
aprotinin, and phenylmethylsulfonyl fluoride [PMSF]) per
50 ml. Tissues were then homogenized and pelleted by
centrifugation (150g  10 minutes). The resultant pellet was
discarded, and the supernatant was reconstituted in homoge-
nization buffer. Tissue homogenates (10 mg of total protein)
were resolved by sodium dodecyl sulfate polyacrylamide gel
electrophoresis on 10% or on 4% to 20% gradient gels
(Invitrogen, San Diego, CA) and transferred to Immobilon P
membranes. The blots were probed with primary antibodies
specific for humanCOX-2 (polyclonal; CaymanChemical) and
actin (I-19; Santa Cruz Biotechnology, Santa Cruz, CA),
according to the manufacturer’s protocol, followed by sec-
ondary antibody (Amersham) andECL detection (Amersham).
Results
COX-2 Expression in Pancreatic Carcinogenesis
A number of published studies have reported elevated
COX-2 expression in pancreatic adenocarcinomas or col-
lectively in PanINs versus normal pancreatic ducts. However,
any specific changes in COX-2 expression at each distinct
pathological stage in pancreatic neoplasia have not been de-
scribed. We first employed a BOP-induced model of hamster
pancreatic carcinogenesis for the measurement of COX-2
expression at every stage of experimental pancreatic neo-
plasia. The highest-grade lesion in each pancreas was iden-
tified in an H&E–stained section, and an adjacent section
was used to detect COX-2 protein expression by immuno-
histochemistry. Thirty invasive ductal adenocarcinomas, 47
PanIN lesions (23 PanIN1, 7 PanIN2, and 17 PanIN3), and
39 normal ducts were identified for analysis. As depicted
in Figure 1A, the normal ducts, PanINs, and invasive adeno-
carcinomas of hamsters are strikingly similar to those of the
human pancreas (Figure 1C).
In Figure 1B, representative examples of COX-2 expres-
sion in normal hamster pancreatic ducts, PanIN1–PanIN3
lesions, and an invasive ductal adenocarcinoma are shown,
and quantitative COX-2 expression data are presented in
Figure 2A and Table 1. Little to no COX-2 staining was
observed in normal ductal cells. There was a marked step-
wise increase in staining as the PanIN lesions progressed
toward malignancy, with the most intense staining in inva-
sive lesions. Average COX-2 expression increased signifi-
cantly from normal to PanIN1 lesions, and then again from
PanIN1 to PanIN2 [Figure 2A; P < .001 by analysis of vari-
ance (ANOVA)]. There was little change in COX-2 expres-
sion between PanIN2 and PanIN3 lesions, and a slight but
statistically significant further increase in invasive lesions
(P < .001, ANOVA). As shown in Table 1, the majority of
normal ducts and most PanIN1 lesions showed little or no
COX-2 staining, PanIN2 and PanIN3 lesions had inter-
mediate or intense staining in approximately equal propor-
tions, and nearly all invasive adenocarcinomas exhibited
intense COX-2 staining.
COX-2 expression was then detected by immuno-
histochemistry in 30 human pancreatic adenocarcinomas.
Figure 1C demonstrates H&E sections of human tumors and
demonstrates a representative example of a normal duc-
tule, PanIN1–PanIN3, and an invasive lesion. Correspond-
ingly, Figure 1D shows COX-2 staining in a normal ductule,
PanIN1–PanIN3, and invasive human pancreas lesions.
An analysis was undertaken to identify normal ductules,
normal ducts, PanIN lesions, and invasive lesions within
30 human pancreas specimens from patients with pancreatic
adenocarcinoma. Normal ductules and ducts were also iden-
tified in five intraductal papillary mucinous neoplasms
(IPMNs), one ampullary cell cancer specimen, and one acinar
cell cancer specimen. Together, the analysis of these spe-
cimens identified 55 normal ductules, 42 normal ducts,
22 PanIN1 lesions, 18 PanIN2 lesions, 13 PanIN3 lesions,
and 30 invasive adenocarcinomas. PanINs were identified
in 25 of 30 patients with pancreatic adenocarcinoma, and
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many of these had more than one PanIN. Figure 2B depicts
the average COX-2 expression score of all normal ductules,
ducts, and lesions identified in a particular stage of pan-
creatic carcinogenesis. COX-2 expression was significantly
higher in all stages of human pancreatic neoplasia than in
normal ductules (P < .001), and it increased in a stepwise
manner with each stage of neoplastic progression up to the
PanIN2 stage (P < .05, ANOVA). PanIN3 lesions also had high
COX-2 expression (higher than PanIN1 but less than PanIN2),
whereas average COX-2 expression was relatively lower in
invasive cancers. Interestingly, among invasive lesions, well-
differentiated lesions had the highest COX-2 expression, with
an average score of 6.1 followed by moderately differentiated
lesions at 5.5 and poorly differentiated lesions at 3.6. A tumor
involving lymph nodes represented on the slides had an
average COX-2 expression score of 8, similar to that of
PanIN3. Alternatively, we alsomeasured the composite score,
whereby each of the 30 human cancer specimens examined
received one score for each normal ductule, duct, or lesion
stage (e.g., PanIN1) represented within that specimen. This
method revealed very similar results (data not shown). Impor-
tantly, the overall pattern of COX-2 expression is consistent
with the pattern observed within individual specimens (i.e.,
within each individual specimen, there is a general trend of
increasing COX-2 expression through the different stages of
pancreatic carcinogenesis that were represented).
Our pathologist also examined the topography and char-
acter of COX-2 staining as a function of the lesion stage
of pancreatic tumorigenesis. Through successive PanIN
stages, there is a higher degree of perinuclear stippling-type
staining. This stippling-type staining is typically very strong in
intensity. In invasive lesions, particularly those with poor
Figure 1. (A) H&E–stained normal hamster pancreas, hamster pancreatic intraepithelial neoplasms (PanIN1, PanIN2, and PanIN3), and invasive pancreatic
adenocarcinoma. (B) COX-2 immunohistochemistry in normal hamster pancreas, hamster pancreatic intraepithelial neoplasms (PanIN1, PanIN2, and PanIN3), and
invasive pancreatic adenocarcinoma. (C) H&E–stained normal human pancreas, human pancreatic intraepithelial neoplasms (PanIN1, PanIN2, and PanIN3), and
invasive pancreatic adenocarcinoma. (D) COX-2 immunohistochemistry in normal human pancreas, human pancreatic intraepithelial neoplasms (PanIN1, PanIN2,
and PanIN3), and invasive pancreatic adenocarcinoma.
440 COX-2 in Pancreatic Neoplasia Crowell et al.
Neoplasia . Vol. 8, No. 6, 2006
differentiation, there is loss of perinuclear stippling, which is
largely replaced by diffuse cytoplasmic staining. This diffuse-
type staining is typically very faint in intensity.
Finally, in a separate analysis of five IPMNs (precancerous
lesions similar to PanINs in that they can progress to inva-
sive pancreatic cancer), we observed a similar trend with in-
creasing neoplastic grade. Average scores were as follows:
ductules, 2; ‘‘normal ducts,’’ 10.7; adenoma, 12; low-grade
dysplasia, 8.6; high-grade dysplasia, 8.5; overall invasive
lesions, 4.25; well-differentiated lesions, 7.5; moderately
differentiated lesions, 4. The trend in the topography and
character of COX-2 staining is mirrored in IPMNs. As a
negative control, we examined acinar cell carcinoma of the
pancreas and ampullary carcinoma, neither of which demon-
strated COX-2 staining of ductal cells.
PGE2 Level (COX-2 Activity) in Pancreatic Cancer
Having established that COX-2 is overexpressed through-
out hamster and human pancreatic neoplasia, we next
sought to determine if this overexpression corresponded
to an increased enzymatic activity of COX-2 in vivo. Two
pair-matched samples of human invasive pancreatic cancer
versus normal tissue were cryopreserved and then ana-
lyzed for COX-2 protein expression by Western blot analy-
sis (Figure 3A). As expected, in both hamster and human
specimens, COX-2 expression in tumor tissue was greater
than in pair-matched normal tissues. Actin is shown, but
in inflammatory-based cancers, such as pancreatic (and
hepatocellular) cancer, higher amounts of actin protein are
typically expressed in tumors than in normal tissues. Coo-
massie blue staining of the same samples (data not shown)
demonstrates nearly equivalent protein loading.
The same pair-matched samples were then subjected
to PGE2 assay to determine PGE2 tissue concentrations.
Figure 3B demonstrates a significantly greater average of
4.7 ± 0.8 pg/mg total protein for PGE2 in human pancreatic
tumor versus an average level of 1.1 ± 0.3 pg/mg total protein
of PGE2 in pair-matched normal tissue (P < .05, Student’s
Figure 1. Continued
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t test). COX-2 activity was then measured by PGE2 produc-
tion in the hamster PC-1 pancreatic ductal adenocarcinoma
cell line–derived tumor and then compared with a normal
pancreas isolated from the same animal. The level of PGE2
in hamster pancreas tumors (1.4 ± 0.2 pg/mg total protein)
was significantly higher than that in normal pancreas (0.1 ±
0.0 pg/mg total protein; P < .05, Student’s t test; Figure 3B).
Anticancer Activity of the Nonselective COX
Inhibitor Sulindac
Based on these results, we hypothesized that sulindac, a
COX inhibitor, would have anticancer activity in a hamster
pancreatic cancer model. Hamsters were treated with either
control or a 0.01% (wt/wt) sulindac diet starting 5 days before
subcutaneous flank injection of a suspension of PC-1 ham-
ster pancreatic ductal adenocarcinoma cells (derived from a
BOP-induced pancreatic adenocarcinoma). After 4 weeks,
tumor incidence in control animals was 78% (18/23) vs 16%
(2/12) in the sulindac group (P < .0005, chi-square analysis;
Figure 4). Sulindac had little effect on hamster tumor growth
when administered orally to animals bearing already estab-
lished PC-1 tumors (D. A. Hertzler and P. L. Crowell, unpub-
lished observations), leading us to conclude that sulindac may
have the greatest effect on tumor engraftment/formation.
Discussion
This study was undertaken to investigate the degree of COX-
2 expression during the multistep process of pancreatic neo-
plasia both in experimental and in human pancreatic cancer.
We have found, as other investigators have previously iden-
tified, that COX-2 expression is elevated in invasive adeno-
carcinomas compared to normal ductal tissues [10,14–25].
Unlike previous studies, however, we have determined that
normal ductules do not express COX-2. Furthermore, we re-
port the novel findings of COX-2 expression in each type of
PanIN lesion, the correlation of COX-2 enzymatic activity
(PGE2 level) with COX-2 expression, and the direct compari-
son of COX-2 expression and activity in the BOP-induced
hamster pancreatic carcinogenesis model versus human
pancreatic tissues.
COX-2 expression varies markedly throughout the patho-
logical process of pancreatic neoplasia. In PanIN lesions, we
determined that there is a highly significant stepwise in-
crease in the expression of COX-2 from normal ducts to
PanIN1 and from PanIN1 to PanIN2 in both human and ex-
perimental pancreatic cancers. The difference between
PanIN2 and PanIN3 lesions is less marked, and, in human
tissues, may be somewhat decreased. COX-2 expression in
hamster invasive adenocarcinomas was higher than in
PanIN2 or PanIN3 lesions, whereas the average level of
COX-2 expression in human invasive adenocarcinomas
was lower than in any PanIN lesions, albeit higher than in
normal ducts. The hamster invasive tumors were typically
well differentiated, whereas the human invasive tumors
were a mixture of well differentiated to poorly differentiated
states. In human tissues, therefore, we evaluated COX-2
Figure 2. (A) COX-2 expression (average score) in hamster pancreatic
neoplasms. Hamster pancreatic cancer was initiated at time 0 with the
chemical carcinogen BOP. On week 42, all hamsters were euthanized, and
lesions were scored by neoplastic stage. COX-2 expression was measured
by immunohistochemistry in the most advanced lesion in each pancreas, and
each lesion was assigned a value of 0 (absent/weak staining), 1 (intermediate
staining), or 2 (intense staining). The data represent the mean ± SEM.
ANOVA indicated that COX-2 expression significantly (P < .001) increased
with each stage of neoplastic progression, except PanIN2 to PanIN3. (B)
COX-2 expression in human pancreatic neoplasms. COX-2 expression was
measured by immunohistochemistry. The COX-2 average expression score
for each ductule, duct, PanIN1–3, and invasive cancer was the multiplicative
factor of the intensity (0–3) times the frequency (0–4) of cells stained for
COX-2. The data represent mean ± SEM. Analysis of variance indicated that
COX-2 expression was significantly different in all stages of neoplasia com-
pared to normal ductules and normal ducts (P < .001) and increased with
each stage of neoplastic progression up to the PanIN2 stage (P < .05).
Table 1. COX-2 Expression in Hamster Pancreatic Carcinogenesis.
Tissue Relative COX-2 Expression [n (%)]
Absent/Weak Intermediate Intense
Normal duct 36/39 (92.3) 3/39 (7.7) 0/39 (0)
PanIN1 14/23 (60.9) 7/23 (30.4) 2/23 (8.7)
PanIN2 0/7 (0) 4/7 (57.1) 3/7 (42.9)
PanIN3 0/17 (0) 9/17 (52.9) 8.17 (47.1)
Invasive ductal
adenocarcinoma
1/30 (3.3) 3/30 (10) 26/30 (86.7)
Hamster pancreatic cancer was initiated at time 0with the chemical carcinogen
BOP. On week 42, all hamsters were euthanized and scored according to the
state of neoplastic progression. COX-2 expression wasmeasured by immuno-
histochemistry in the most advanced lesion in each pancreas, and each lesion
was assigned a value of 0 (absent/weak staining), 1 (intermediate staining), or
2 (intense staining). The data represent the number of animals with tumors
staining at the indicated level/total number of animals and the percentage of
animals with tumors staining at the indicated level.
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expression in invasive lesions as a function of differentiation
status. Well-differentiated lesions expressed COX-2 to the
highest degree, and there was less expression of COX-2
in moderately and poorly differentiated lesions. Thus, the
different trends for COX-2 expression in hamster versus
human invasive cancers may be attributable to the different
states of differentiation in the tumors.
We found that COX-2 activity (PGE2 level) correlated well
with COX-2 expression. COX-2 activity was significantly ele-
vated in pair-matched human tumors versus normal speci-
mens. In addition, in specimens that did not have a pair
match, aggregate data suggest that the tumor has an activity
greater than the average activity expressed by normal non–
pair-matched samples. COX-2 activity was also examined
in the PC-1 hamster pancreatic cancer model. Mirroring
human data, COX-2 activity was significantly elevated in
the tumor versus the normal pancreas, although the fold dif-
ference of PGE2 detected in hamster tumors versus normal
tissues (f14-fold) was higher than in humans (f4-fold),
possibly due to the very low levels of PGE2 detected in normal
hamster control pancreas. Correspondingly, the higher basal
level of PGE2 in ‘‘normal’’ human pancreasmay be secondary
to this tissue being adjacent to cancer (unlike the normal
control pancreas in the hamster). Human pancreatic cancer
often results in fibrosis and an intense stromal reaction in
the rest of the pancreas that may be responsible for the ele-
vation of PGE2. Interestingly, COX-2 expression even in
‘‘normal’’ ducts (pre-PanIN) had a stepwise increase as the
degree of stromal reaction surrounding the duct increased.
Thus, the effect of the microenvironment on these tumors in
relation to COX-2 may be quite significant.
From these data, it appears that COX-2 may be very im-
portant in, and perhaps even a contributor to, pancreatic
Figure 3. (A) COX-2 expression in human and hamster pancreatic neoplasms. Pair-matched samples of human or hamster invasive pancreatic cancer versus
normal tissue were cryopreserved and then analyzed for COX-2 expression by Western blot analysis. A representative Western blot is shown of both human and
hamster pancreatic neoplasms (T, tumor) compared to pair-matched normal control tissues from the same patient or hamster (NL, normal). Actin, which is known to
be elevated in tumor samples, is also shown. Gels stained with Coomassie blue confirmed an equivalent overall protein loading of the samples (data not shown).
(B) COX-2 activity in human and hamster pancreatic neoplasms. Pair-matched samples of human or hamster invasive pancreatic cancer versus normal tissue were
cryopreserved and then analyzed for COX-2 activity by PGE2 assay. The assay is based on competition between unlabeled PGE2 and a fixed quantity of
peroxidase-labeled PGE2 for binding to a PGE2-specific antibody bound to a plate coated with goat antimouse immunoglobulin. The human tumor PGE2 level [4.7 ±
0.8 pg/g total protein (mean ± SEM)] was significantly higher than that of normal tissue [1.1 ± 0.3 pg/g total protein (mean ± SEM), n = 3, t-test, P < .05]. Similarly,
the hamster tumor PGE2 level [1.4 ± 0.2 pg/g total protein (mean ± SEM)] was significantly higher than that in normal tissue [0.1 ± 0.0 pg/g total protein (mean ±
SEM), n = 7, t-test, P < .05].
Figure 4. Inhibition of PC-1 hamster pancreatic cancer engraftment/formation
with the nonselective COX inhibitor sulindac. Male Syrian golden hamsters
were fed either control or 0.01% (wt/wt) sulindac diet starting 5 days before the
injection of hamster PC-1 pancreatic adenocarcinoma cells. The data rep-
resent the percentage of 23 control and 12 sulindac animals with tumor 4weeks
after PC-1 cell injection (*P < .0005 vs control by chi-square analysis).
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neoplasia. Based on the pattern of expression of COX-2
observed, we hypothesize that it may be very important
in the early stages of human pancreatic carcinogenesis;
namely, the PanIN1 and PanIN2 lesions. The BOP-induced
hamster pancreatic carcinogenesis model appears to be
quite suitable for studying the role of COX-2 in pancre-
atic carcinogenesis, particularly in the early PanIN1 and
PanIN2 stages.
COX-2 has been shown in other cancers to play a signifi-
cant role in carcinogenesis. In colorectal cancer, it has been
shown to have a chemotherapeutic and chemopreventive
role in treating the disease [4]. Some demographic data sug-
gest that individuals who take aspirin have a lower risk of
developing pancreatic cancer [29], although other studies
have reported no effect or an increased risk [30–33]. We
report that oral administration of sulindac reduced the inci-
dence of pancreatic tumor formation in the PC-1 hamster
model, suggesting that sulindac or other nonsteroidal anti-
inflammatory drugs (NSAIDs) may also have chemothera-
peutic potential in pancreatic cancer cells. By Western blot
analysis, PC-1 cells express COX-2 protein but no detect-
able levels of COX-1. This suggests that, in the PC-1 hamster
pancreatic cancer model, sulindac is targeting COX-2, other
COX-independent pathways, or both. COX-2 inhibitors,
such as nimesulide and celecoxib (Celebrex; Pfizer Inc.,
Ann Arbor, MI), have been previously shown to inhibit pan-
creatic tumorigenesis in the BOP-induced hamster model
[34,37,38]. Even if COX-1 does not effect tumorigenesis,
the absence of COX-1 inhibition, as is the case with COX-
2–selective inhibitors, may have untoward effects on an
organism’s normal cells. COX-2–selective inhibitors have
recently come under scrutiny by the Food and Drug Admin-
istration due to apparent cardiovascular side effects with
long-term use; thus, a nonselective COX inhibitor, such as
sulindac, employed in these studies may be more suitable
for treatment.
Although NSAIDs are known to target COX, antitumor
effects may be mediated by targeting COX-independent path-
ways as well, such as NF-nB and cGMP-dependent phospho-
diesterase [39]. Future studies should further explore the role
of COX-2 in the chemoprevention of experimental and human
pancreatic cancers, with emphasis on intervention in the early
stages of carcinogenesis. The hamster pancreatic carcino-
genesis models are reasonable models to use in undertaking
these studies [34–38].
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